XXXX : clinical outcomes after more than five years of follow-up.

@entity1 @entity6275 @entity6592 @entity625 @entity1569 @entity1910 @entity29 @entity158 @entity717
OBJECTIVE: To determine the clinical outcomes of @entity1 with @entity6275 ( @entity6275 ). STUDY DESIGN: Inception cohorts of @entity1 with @entity6275 were established at two tertiary pediatric centers. Outcome data were obtained through review of hospital charts, interview and examination of @entity1 , and completion of questionnaires by @entity1 . RESULTS: Of 45 eligible subjects, 23 (51%) were assessed. Median time since diagnosis was 13 years (range, 6-25). At evaluation, 6 (26%) had active disease; 18 (78%) had Health Assessment Questionnaire scores of 0 (no/minimal @entity717 ), and 5 had scores >0. Some impairment was seen in all domains of measurement of quality-of-life test, especially those concerning nonphysical aspects of health. Six (26%) subjects continued to have @entity158 as a result of @entity6275 . Associated medical problems included @entity625 in 6, @entity6592 in 3, @entity1569 in 5, recurrent @entity1910 in 2, and @entity29 in 3. CONCLUSIONS: Long-term clinical outcomes for @entity1 with @entity6275 appear to be generally good, with most subjects having no evidence of disease activity or sequelae. However, a number of subjects had persistent disease and, therefore, remain at risk of physical and psychologic complications. Further research is required to identify @entity1 at risk for persistent disease, and to determine therapies that may prevent morbidity.
